EphB2 Receptor Promotes Dermal Fibrosis in Systemic Sclerosis

Area of Science:

• Dermatology
• Molecular Biology
• Cell Signaling

Background:

• Erythropoietin-producing hepatocellular (Eph)/Ephrin cell-cell signaling is implicated in fibrogenesis.
• Dermal fibrosis is a key feature of systemic sclerosis (SSc).

Purpose of the Study:

• To investigate the role of EphB2 receptor tyrosine kinase in mediating dermal fibrosis in SSc.
• To test if EphB2 is a therapeutic target for SSc.

Main Methods:

• Assessed EphB2 expression in human SSc skin and fibroblasts.
• Utilized EphB2-knockout, kinase-dead, and overactive mutant mice in bleomycin and Tsk1/+ fibrosis models.
• Conducted in vitro studies on SSc fibroblasts and in vivo studies on fibroblast-specific Ephb2-deficient mice.

Main Results:

• EphB2 expression is upregulated in SSc skin and fibroblasts, and in animal models of fibrosis.
• EphB2 signaling drives dermal fibrosis in mouse models.
• Transforming growth factor-β (TGF-β) upregulates EphB2 in fibroblasts, and EphB2 inhibition reduces TGF-β-induced differentiation and fibrosis.

Conclusions:

• TGF-β-mediated EphB2 overexpression and signaling are critical in SSc dermal fibrosis.
• EphB2 is a potential therapeutic target for SSc.